ESR2 and cancer: Notably, studies of ESR2 polymorphisms (e.g., rs1256049, rs4986938) mainly focus on risk rather than prognosis—some report increased endometrial cancer risk for rs1256049, while rs4986938 shows no overall cancer-risk link—highlighting the importance of distinguishing risk alleles from variants that truly affect prognosis when interpreting survival [65].